The glucose-dependent insulinotropic polypeptide (GIP), another gastrointestinal hormone, plays a similar role to the GLP-1 hormone, and GIP receptors are another target for weight-loss drugs
The FDAs approval for its use specifically in weight management has opened up new avenues for individuals struggling with obesity
CNS side effects including sedation and restlessness (akathisia) occur even at short-term doses in some patients
GLP-1 benefits extend to anyone with cardiovascular risk factors, making these medications relevant for a broad population seeking genuine heart protection alongside weight management
If constipation persists beyond six weeks despite lifestyle modifications, switching to oral semaglutide or exploring the Precision Peptide Genetic Test to identify peptide-pathway predispositions may help optimize your therapy
After 72 weeks of treatment, more than half of the patients in the medication group lost at least 10% of their body weight and had a smaller waist circumference
